Background
Biohaven Pharmaceuticals is studying rimegepant, for the treatment of Trigeminal Neuraligia (TN). If you are 18 years or older and suffer from TN, you may qualify.
This is a Phase 2 multi-center clinical trial to evaluate the safety and efficacy of Rimegepant compared to placebo for subjects with Trigeminal Neuralgia. Placebo is inactive substance and does not contain any study medication.
Health insurance is not required to take part in this study and compensation for participation may also be provided.
TN Study Details
This is a 7-9 week study which will require several clinic visits. Patients will receive both active medication (rimegepant) and placebo.
Why Participate?
By joining this study, you will help contribute to our understanding of this disorder and the potential effectiveness of rimegepant for the treatment of TN. You will also receive:
- Study-related evaluations of your TN-related symptoms and overall health.
- Investigational drug and study-related care at no cost to you.
- You may receive compensation for your participation
